Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc.
(NYSE American: DSS), along with its scientific research partner
Global Research and Discovery Group Sciences, (GRDG) announced it
had received a positive report regarding the potential
international patentability of its proprietary compound Equivir to
treat viral infections which has shown potential to limit the
occurrence of, and reduce, the risk or severity of viral outbreaks.
What is a Global Patent Application?Patents
awarded on a country basis, and, as such, are only enforceable
within that country only, leaving the door open for the possibility
of someone in another country to apply for a patent in their
region, limiting the reach of the initial patent-holder. Global
patent applications can be filed with the World Intellectual
Property Organization (WIPO), an agency operating under the United
Nations and is responsible for administering several international
treaties relating to patents and other intellectual property
rights. There are a total of 184 members of WIPO, including the
U.S., China, and many European countries.
WIPO allows inventors to file one patent application, indicating
on the application in which member states he or she wishes to
obtain protection. This eliminates the need to file several patent
applications simultaneously with different member states. In
addition, WIPO, though a divisional referred to as the
International Searching Authority (“ISA”), performs a search for
potential prior art and a preliminary examination of the claims.
The ISA issues its finding in a Patentability Report.
The Patentability Report received from the ISA regarding
International application No. PCT/US2021/22538, directed the use of
a composition containing Myricetin and G-hesperidin to treat viral
infections determined that no prior art was found which would
preclude the possibility of obtaining patent protection and that
all claims were patentable.
“The receipt of this clean patentability report for Equivir’s
international patent application is demonstrative of our desire to
make Impact Biomedical’s antiviral innovations available to protect
people worldwide,” said Frank. D. Heuszel, CEO of DSS.
This is the third stepThis is the third
positive step for Equivir, which is believed can limit the spread
and severity of several viruses that lower the quality of life for
people in the U.S. and abroad.
The first step occurred when Impact BioMedical received its
first Equivir patent (US 10,383,842), which focused on influenza,
from the U.S. Patent and Trademark Office on August 20, 2019.
Less than two years later, on June 15, 2021, the USPTO granted a
second patent, this time focused on both Ebola and the
rhinovirus.
How does Equivir work?Equivir is believed to
block the entry of virus to host cells and thereby prevent
infection and replication in host cells. Taken much like a
multivitamin, Equivir is a novel blend of FDA Generally Recognized
as Safe (GRAS) eligible polyphenols.
In addition to its effects against various serotypes of
influenza, Equivir is also believed to block the entry of Ebola
virus into host cells which can prevent Ebola Virus Disease (EVD)
and Ebola Hemorrhagic fever (EHF). These diseases are rare, but
severe and often fatal in humans, particularly in sub-Saharan
Africa. Ebola has a 90-percent death rate, according to the World
Health Organization. Rhinovirus is the most common viral infectious
agent in humans and is the predominant cause of the common
cold.
Equivir has also possible use in addressing the side-effects and
duration of viral infections and SARS COV2.
"Over the past two years, we have all experienced the impact of
a virus,” said Daryl Thompson, Impact BioLife’s Director of
Scientific Initiatives and founder of the advanced research company
GRDG Sciences, LLC. “It is hoped that Equivir can be used as a
deployable strategic defense for a broad spectrum of viral
infections.”
“It is Equivir’s potential against a wide variety of infectious
diseases, coupled with a relatively straightforward manufacturing
process which makes Equivir of potential value around the world,”
according to GRDG's Chief Scientific Advisor Dr. Roscoe M. Moore,
Jr., United States Assistant Surgeon General (Retired) and former
Epidemic Intelligence Service (EIS) Officer at U.S. Center for
Disease Control and Prevention. “While the threat of viral
infections remains significant, it is Equivir’s ability to be
quickly deployed as a working solution wherein such a treatment can
be significant.”
About Impact BioMedical, Inc.Impact BioMedical,
Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS.
Impact BioMedical strives to leverage its scientific know-how and
intellectual property rights to provide solutions that have been
plaguing the biomedical field for decades. By tapping into the
scientific expertise of GRDG Sciences, LLC, Impact BioMedical
pledges to undertake a concerted effort in the R&D, drug
discovery and development for the prevention, inhibition, and
treatment of neurological, oncological and immuno related diseases.
For more information on Impact BioMedical visit
http://impbio.com/.
About DSS, Inc.DSS is a multinational company
operating business segments in blockchain security, direct
marketing, healthcare, consumer packaging, real estate, renewable
energy, securitized digital assets, securities trading and fund
management, and banking, lending, and finance. Its business model
is based on a distribution sharing system in which shareholders
receive shares in its subsidiaries as DSS strategically unlocks
value through IPO spinoffs. Under new leadership since 2019, DSS
has built the necessary foundation for sustainable growth through
the acquisition and formation of a diversified portfolio of
companies positioned to drive profitability in five high-growth
sectors. These companies offer innovative, flexible, and real-world
solutions that not only meet customer needs, but create sustainable
value and opportunity for transformation.
For more information on DSS visit http://www.dssworld.com
Investor Contact:Dave Gentry, CEORedChip Companies
Inc.407-491-4498DSS@redchip.com
Safe Harbor DisclosureThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements related to
the Company's intended use of proceeds and other statements that
are not historical facts. Forward-looking statements are based on
management's current expectations and are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. These risks and uncertainties,
many of which are beyond our control, include: risks relating to
our growth strategy; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
risks relating to the results of development activities; our
ability to attract, integrate and retain key personnel; our need
for substantial additional funds; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings, including, without limitation, our reports on Forms 8-K,
10-K and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations, and beliefs. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions, or circumstances on which any such statement is based,
except as required by law.
DSS (AMEX:DSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
DSS (AMEX:DSS)
Historical Stock Chart
From Apr 2023 to Apr 2024